KAKEN PHARMACEUTIAL CO., LTD. Logo

KAKEN PHARMACEUTIAL CO., LTD.

Develops and markets pharmaceuticals for dermatology, orthopedics, and surgery.

4521 | T

Overview

Corporate Details

ISIN(s):
JP3207000005
LEI:
Country:
Japan
Address:
文京区本駒込二丁目28番8号

Description

Kaken Pharmaceutical Co., Ltd. is a research and development-driven company that develops, manufactures, and markets prescription pharmaceuticals, medical equipment, and agrochemicals. The company's primary focus is on pharmaceuticals, with significant expertise in dermatology, orthopedics, and surgery. Its portfolio of main products includes Clenafin for onychomycosis, Artz for osteoarthritis, Fiblast for wound healing, and Ecclock for primary axillary hyperhidrosis. Kaken's research and development efforts are concentrated on specific fields, including the immune system, nervous system, and infectious diseases, to create innovative drugs. The company also has business activities in real estate.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-06-29 07:53
確認書
Japanese 8.7 KB
2023-06-29 07:52
有価証券報告書-第103期(2022/04/01-2023/03/31)
Japanese 1.4 MB
2023-02-10 02:26
四半期報告書-第103期第3四半期(2022/10/01-2022/12/31)
Japanese 194.5 KB
2023-02-10 02:25
確認書
Japanese 8.7 KB
2022-11-11 03:07
確認書
Japanese 8.7 KB
2022-11-11 03:05
四半期報告書-第103期第2四半期(令和4年7月1日-令和4年9月30日)
Japanese 212.2 KB
2022-08-10 03:40
確認書
Japanese 8.7 KB
2022-08-10 03:38
四半期報告書-第103期第1四半期(令和4年4月1日-令和4年6月30日)
Japanese 181.6 KB
2022-06-29 08:45
内部統制報告書-第102期(令和3年4月1日-令和4年3月31日)
Japanese 23.7 KB
2022-06-29 08:44
確認書
Japanese 8.7 KB
2022-06-29 08:43
有価証券報告書-第102期(令和3年4月1日-令和4年3月31日)
Japanese 1.1 MB
2022-02-10 01:47
四半期報告書-第102期第3四半期(令和3年10月1日-令和3年12月31日)
Japanese 206.9 KB
2021-11-11 05:10
四半期報告書-第102期第2四半期(令和3年7月1日-令和3年9月30日)
Japanese 223.7 KB
2021-08-12 03:01
四半期報告書-第102期第1四半期(令和3年4月1日-令和3年6月30日)
Japanese 187.6 KB
2021-06-29 07:32
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all KAKEN PHARMACEUTIAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KAKEN PHARMACEUTIAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KAKEN PHARMACEUTIAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.